The founder and director of CHOP's Center for Fetal Diagnosis and Treatment, Dr. Adzick is an innovator in the field of fetal medicine, pursuing groundbreaking prenatal treatment for debilitating birth defects. He led the NIH-funded "Management of Myelomeningocele Study" (MOMS) at CHOP, a breakthrough research program that showed fetal surgery for spina bifida results in significantly improved outcomes.
Dr. Stanley’s lab has identified many of the genes and syndromes associated with congenital hyperinsulinism including ABCC8, GCK, GLUD1, and Turner and Beckwith syndromes. Working with clinical and rodent model studies, his lab team has identified distinctive phenotypes of these disorders, including diazoxide unresponsiveness, leucine sensitivity, and protein sensitivity. Dr. Stanley continues to seek new diagnostic and treatment paradigms for infants with acquired and genetic disorders of hyperinsulinism.
Dr. De Leon-Crutchlow’s translational research program focuses on examining the pathophysiology of disorders of insulin regulation, identifying novel therapeutic targets, and developing new therapies for these conditions. The program approach includes patient-oriented research and bench research employing mouse models and primary islet cultures.
As a pediatric endocrinologist and director of the Congenital Hyperinsulinism Center at Children's Hospital of Philadelphia (CHOP), Diva De León-Crutchlow, MD, specializes in the diagnosis and management of hyperinsulinism (HI) and other hypoglycemia disorders.
It has been a whirlwind week for most Americans, so if you need to break away from political news to catch up with your science news, you've come to the right place. This installment of In the News starts with an important study for patients with rare primary immunodeficiency diseases at risk of side effects from the rubella vaccine. Next,